SCOTTSDALE, Ariz., Feb. 26 /PRNewswire/ -- MedPredict Market Research,
a global provider of pharmaceutical competitive intelligence and market
research, has published a new report providing critical strategic insight
for pharma and biotech companies with a stake in the market for Rheumatoid
Arthritis (RA) therapies.
In this report, entitled MedPredict Thought Leader Insight & Analysis:
Rheumatoid Arthritis Q1 2008, MedPredict's global Thought Leader Panel
debates tough questions facing drug developers:
-- How should rheumatologists sequence/stack biologicals? What will
challenge the anti-TNF paradigm? T-cell? B-cell? Mesenchymal cell?
-- How big of a benefit will oral dosing provide in this patient
population? Syk? Jak? p38? CCR? Will orals move RA treatment into
-- What do they hear from Pharma? What will Wyeth do when they return to
Amgen the rights to etanercept? How strong is AstraZeneca's
commitment to arthritis?
-- Why is it so hard to treat gout?
"There continue to be significant unmet needs in this market," says
MedPredict President Jeffrey D. Berk. "According to our Panelists, only
half of RA patients achieve remission on their first biological therapy and
these remissions aren't durable. Even with completely new options many
patients are left under-satisfied and demanding better results from their
physicians. This report sheds light on these unmet needs and reveals
Panelists' views of the most promising candidates."
Drugs/Companies mentioned in this report: allopurinol; febuxostat
(Teijin/Ipsen/TAP); Puricase (pegloticase; Savient); Remicade (infliximab;
Centocor/Schering-Plough/Essex), Enbrel (etanercept; Wyeth/Amgen); Humira
(adalimumab; Abbott), Orencia (abatacept; Bristol-Myers Squibb); MabThera
(rituximab; Roche/Biogen/Genentech); methotrexate (generic); denosumab
(Amgen); golimumab (Centocor/Schering-Plough/Essex); Actemra (tocilizumab;
Roche/Chugai); Cimzia (certolizumab; UCB); GA101 (anti-BR3-Fc/anti-BR3 MAb
Biogen/Genentech); LymphoStat-B(R) (belimumab; Human Genome Sciences/GSK);
Atacicept (TACI-Ig; ZymoGenetics/Merck-Serono); BMS-582949 (BMS); 856553
(GSK); CP-690550 (Pfizer); INCB18424 (Incyte); tamatinib (R788; Rigel);
baminercept (BG9924; Biogen); MLN-3897 (Millennium/Sanofi-Aventis); AZD5672
(AstraZeneca); RWJ-445380 (Alza/J&J); AZD9056 (AstraZeneca); everolimus
(RAD-001; Novartis); MM-093 (Merrimack)
This report can be purchased by contacting MedPredict.
MedPredict (http://www.medpredict.com) maintains a proprietary database
of over 1,000 global physician thought leaders, including 40+ specialties
in 30+ therapeutic categories. Based on primary interviews with these
thought leaders, MedPredict publishes periodic reports in each category to
keep clients up-to-date on emerging trends and competitive activity. The
reports include thought leader reactions to recent publications and medical
conferences, as well as clinical, regulatory and marketing activity.